Ventyx Biosciences (VTYX) Competitors $1.14 +0.08 (+7.01%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. AVIR, ESPR, SLRN, CADL, ACB, PVLA, IMMP, OLMA, CMPX, and DRUGShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Atea Pharmaceuticals (AVIR), Esperion Therapeutics (ESPR), Acelyrin (SLRN), Candel Therapeutics (CADL), Aurora Cannabis (ACB), Palvella Therapeutics (PVLA), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Compass Therapeutics (CMPX), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Atea Pharmaceuticals Esperion Therapeutics Acelyrin Candel Therapeutics Aurora Cannabis Palvella Therapeutics Immutep Olema Pharmaceuticals Compass Therapeutics Bright Minds Biosciences Atea Pharmaceuticals (NASDAQ:AVIR) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Which has more volatility & risk, AVIR or VTYX? Atea Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Do analysts recommend AVIR or VTYX? Atea Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 98.35%. Ventyx Biosciences has a consensus target price of $10.00, suggesting a potential upside of 773.36%. Given Ventyx Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Ventyx Biosciences is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is AVIR or VTYX more profitable? Atea Pharmaceuticals' return on equity of -34.90% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -34.90% -32.38% Ventyx Biosciences N/A -54.94%-50.01% Does the MarketBeat Community believe in AVIR or VTYX? Ventyx Biosciences received 12 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. However, 47.50% of users gave Atea Pharmaceuticals an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformAtea PharmaceuticalsOutperform Votes1947.50% Underperform Votes2152.50% Ventyx BiosciencesOutperform Votes3146.97% Underperform Votes3553.03% Which has stronger valuation & earnings, AVIR or VTYX? Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$135.96M-$2.00-1.51Ventyx BiosciencesN/AN/A-$192.96M-$1.98-0.58 Do institutionals & insiders believe in AVIR or VTYX? 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 17.8% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of Ventyx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to AVIR or VTYX? In the previous week, Atea Pharmaceuticals had 3 more articles in the media than Ventyx Biosciences. MarketBeat recorded 3 mentions for Atea Pharmaceuticals and 0 mentions for Ventyx Biosciences. Atea Pharmaceuticals' average media sentiment score of 0.07 beat Ventyx Biosciences' score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Atea Pharmaceuticals Neutral Ventyx Biosciences Neutral SummaryVentyx Biosciences beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.44M$6.42B$5.26B$7.15BDividend YieldN/A3.21%5.45%4.34%P/E Ratio-0.496.8821.7617.56Price / SalesN/A234.85381.5796.78Price / CashN/A65.6738.2534.62Price / Book0.285.976.443.92Net Income-$192.96M$142.98M$3.21B$247.36M7 Day Performance4.09%1.91%0.93%0.43%1 Month Performance-13.26%-12.60%-9.54%-7.89%1 Year Performance-74.38%-7.58%11.87%0.35% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences1.4566 of 5 stars$1.15+7.0%$10.00+773.4%-76.1%$81.44MN/A-0.4930AVIRAtea Pharmaceuticals2.6747 of 5 stars$2.78-0.4%$6.88+147.5%-20.2%$237.76MN/A-1.3470Gap DownESPREsperion Therapeutics3.5376 of 5 stars$1.20-2.4%$6.75+462.5%-51.3%$237.42M$332.31M-1.88200Gap DownSLRNAcelyrin3.5487 of 5 stars$2.31-4.9%$9.60+315.6%-56.1%$232.64MN/A-0.94135Short Interest ↓News CoveragePositive NewsCADLCandel Therapeutics2.1655 of 5 stars$4.84+0.4%$21.00+333.9%-11.6%$228.62M$120,000.00-2.8060Short Interest ↑ACBAurora Cannabis0.4228 of 5 stars$4.05+1.0%N/A-31.3%$227.67M$320.81M81.021,340PVLAPalvella Therapeutics3.5068 of 5 stars$20.07-16.3%$43.50+116.7%N/A$221.15M$42.81M-1.66N/APositive NewsIMMPImmutep1.0843 of 5 stars$1.42-5.3%$8.50+498.6%-31.6%$218.34M$5.14M0.002,021Gap DownOLMAOlema Pharmaceuticals3.0171 of 5 stars$3.18-2.2%$27.67+770.0%-55.5%$217.30MN/A-1.4570Short Interest ↓News CoveragePositive NewsCMPXCompass Therapeutics3.2512 of 5 stars$1.57+7.5%$13.38+751.9%+19.0%$217.10M$850,000.00-4.2420Analyst ForecastShort Interest ↑News CoverageGap DownDRUGBright Minds Biosciences3.0074 of 5 stars$29.25-8.7%$84.33+188.3%+2,856.3%$206.04MN/A-172.05N/ANews CoverageGap Up Related Companies and Tools Related Companies Atea Pharmaceuticals Competitors Esperion Therapeutics Competitors Acelyrin Competitors Candel Therapeutics Competitors Aurora Cannabis Competitors Palvella Therapeutics Competitors Immutep Competitors Olema Pharmaceuticals Competitors Compass Therapeutics Competitors Bright Minds Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTYX Stock Free VTYX Stock Alerts